Glassman has always been a fighter, an us-versus-them kind of guy, and as his company has grown, so has his arsenal: CrossFit now has seven lawyers on staff and at any given time is engaging 12 to 20 outside legal firms to pursue trademark-infringement cases. CrossFit has a database of more than 5,000 possible infringements and is litigating a dozen lawsuits in the U.S. and several more internationally.
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”